U-ZOLE ( TABLET )

• Systemic mycosis including histoplasmosis, non-meningeal coccidioidomycosis, paracoccidioidomycosis and blastomycosis treatment and, in AIDS and other immunosuppressed patients, prophylaxis of cryptococcal meningitis
• Oesophageal and oropharyngeal candidiasis, vaginal candidiasis and systemic candidiasis.

Source : IAP Pediatric Drug Formulary
Newborn-Systemic candidiasis and cryptococcosis Oral/IV 6-12mg/kg every 72 hr in <14 day, every 48 hr in 14-28 day and every 24 hr in > 28 day olds. Mucosal candidiasis 3mg/kg in same intervals. Children: Mucosal candidiasis - Oral/IV loading dose 6mg/kg followed by 3 mg/kg once daily for 7-14 days. Systemic candidiasis and cryptococcosis - 6-12 mg/kg daily once (max 400 mg) - dose dependent on severity of infection Prophylaxis of fungal infection in immuncocompromised 3-12 mg/kg once daily (max 400 mg) dose dependent on extent and duration of neutropenia.

Source : NFI National Formulary of India

• Adult- Mucosal: 50 to 100 mg daily for 14 to 30 days. Vaginal: 150 mg as a single dose.
• Oral: systemic loading dose of 400 mg on first day and thereafter 200 to 400 mg once daily for at least 28 days.

Prophylaxis of fungal infection:

50 to 100 mg once daily.

• Sensitivity to primaquine
• Infants below 1 year of age
• Alcohol
• Coadministration of cisapride, terfenadine

• Renal impairment 
• Lactation
• Monitor liver functiondiscontinue if signs or symptoms of hepatic disease (risk of hepatic necrosis)
• Interactions
• Pregnancy
• Immunocompromised patients

• Nausea, vomiting, abdominal pain
• Flatulence, diarrhoea
• Headache, taste disturbance, hepatic disorders, dizziness, seizures, alopecia, pruritus
• Rash (withdraw treatment)
• Angioedema, anaphylaxis, bullous lesions, toxic epidermal necrolysis and erythema multiforme (Stevens-Johnson syndrome) reported (skin reactions more common in AIDS);
• Hyperlipidaemia, leukopenia, thrombocytopenia, hypokalaemia

Store in an airtight container